GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » TFBS Bioscience Inc (ROCO:6939) » Definitions » EBIT

TFBS Bioscience (ROCO:6939) EBIT : NT$-24.3 Mil (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is TFBS Bioscience EBIT?

TFBS Bioscience's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was NT$-18.3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was NT$-24.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. TFBS Bioscience's annualized ROC % for the quarter that ended in Jun. 2024 was -10.15%. TFBS Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -8.30%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. TFBS Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -9.07%.

TFBS Bioscience EBIT Historical Data

The historical data trend for TFBS Bioscience's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TFBS Bioscience EBIT Chart

TFBS Bioscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EBIT
0.69 7.32 31.36 5.38

TFBS Bioscience Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial 23.17 8.19 11.35 -5.97 -18.33

Competitive Comparison of TFBS Bioscience's EBIT

For the Diagnostics & Research subindustry, TFBS Bioscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TFBS Bioscience's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, TFBS Bioscience's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where TFBS Bioscience's EV-to-EBIT falls into.


;
;

TFBS Bioscience EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-24.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TFBS Bioscience  (ROCO:6939) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

TFBS Bioscience's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=-51.716 * ( 1 - -0.91% )/( (430.19 + 598.428)/ 2 )
=-52.1866156/514.309
=-10.15 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1448.042 - 38.507 - ( 979.345 - max(0, 84.879 - 1072.849+979.345))
=430.19

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1420.824 - 38.94 - ( 784.068 - max(0, 88.088 - 871.544+784.068))
=598.428

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

TFBS Bioscience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-36.668/( ( (337.721 + max(22.434, 0)) + (512.202 + max(10.81, 0)) )/ 2 )
=-36.668/( ( 360.155 + 523.012 )/ 2 )
=-36.668/441.5835
=-8.30 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(64.671 + 8.843 + 3.8699999999999) - (38.507 + 0 + 16.443)
=22.434

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(45.044 + 10.649 + 12.835) - (38.94 + 0 + 18.778)
=10.81

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

TFBS Bioscience's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=-24.305/267.859
=-9.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TFBS Bioscience EBIT Related Terms

Thank you for viewing the detailed overview of TFBS Bioscience's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

TFBS Bioscience Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » TFBS Bioscience Inc (ROCO:6939) » Definitions » EBIT
Comparable Companies
ROCO:6615 TPE:6645 ROCO:7595 ROCO:6847 ROCO:6661 ROCO:4160 ROCO:4153 ROCO:1784 TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD WAT NTRA LH DGX
Traded in Other Exchanges
N/A
Address
No. 103, Lane 169, Kang-ning Street, 3rd Floor, Xizhi District, New Taipei, TWN
Website
https://www.tfbsbio.com
TFBS Bioscience Inc is a Contract Research Organization (CRO) providing biological testing in Taiwan. Its services include viral vector manufacturing for cell and gene therapy products and biosafety testing and product release testing for cell and gene therapy products, vaccines, and biologic products.

TFBS Bioscience Headlines

No Headlines